For research use only. We do not sell to patients. GMP Grade · Kg-scale manufacturing available
Ionizable lipids / SM-102
SM-102 chemical structure
Product imageResearch use only
CAT. NO. DC52025Featured

SM-102 GMP Grade

Pack size & price

USD
Total$200
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

SM-102 is an ionizable lipid used in LNP research for mRNA delivery. A controlled mouse study compared SM-102 with ALC-0315 and cKK-E12 using matched helper lipids, measuring intramuscular reporter expression, antibody responses, inflammatory markers and storage-dependent potency.

Research category: Ionizable lipids for in vivo T-cell engager

In vivo T-cell engager research

SM-102 LNPs delivered self-amplifying RNA encoding a CLDN6 nanobody-based T-cell engager, with circulating expression and antitumor studies in mice. Route: Intravenous.

Zhu et al. Journal of Nanobiotechnology 24, 415 (2026); Figure 3 (SM-102 formulation), Figures 5–7 (in vivo studies). DOI: 10.1186/s12951-026-04319-z.

Manufacturing & quality capability

GMP-grade supply for toxicology, clinical-stage development and scale-up

DC Chemicals can supply SM-102 (DC52025) as a GMP-grade ionizable lipid material for customer toxicology programs and clinical-stage formulation development. Kg-scale production capability is available for qualified projects, subject to technical review, batch planning, quality agreement and batch-specific release requirements.

GMP-grade material

Available with batch-specific identity, purity, residual-solvent, water, elemental-impurity, endotoxin and bioburden testing. Quality documentation can be aligned with the customer's qualification package.

Toxicology and clinical-stage support

Suitable as a lipid raw material for customer-led toxicology studies and clinical-stage formulation development. Final suitability remains subject to the customer's formulation, QA and regulatory assessment.

Kg-scale manufacturing

Production can be planned from research quantities through kilogram scale, with project-specific lead time, batch size, analytical release testing and packaging arranged in advance.

Representative GMP-grade COA results - Batch C10101-N250301

98.9%Main peak purity
1.1%Total impurities
0.21%SM-102-IMP5
0.02%Water content
<0.05 EU/mgEndotoxins
<10 CFU/gTAMC / TYMC

Issued COA: Lot C10101-N250301; manufacture date 20 March 2025; retest date 19 March 2027. Refer to the issued certificate for batch-specific quality results.

COA & quality information

Quality and regulatory note: “GMP-grade” describes the grade of the supplied lipid material and its supporting quality documentation. It does not mean that this lipid itself is an approved drug substance or regulatory-authorized clinical material. Customers remain responsible for qualification, formulation, sterility strategy, release criteria and regulatory use.

Open full Formulation & Performance →

Literature evidence · DC52025

Formulation & Performance

The study uses a PEG phospholipid. Its controlled formulation and storage results should not be substituted for the composition or stability of commercial vaccines.

Reported performance refers to the complete research formulation and the stated experimental model.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
SM-102DC52025710.1653500.355083
DSPCDC57005790.15100.079015
CholesterolDCD-041386.6538.50.148860
PEG2000 PE (14:0 in Methods)Not uniquely mappedNot established1.5Not calculable from disclosed data

SM-102/DSPC/cholesterol/PEG2000 PE = 50:10:38.5:1.5 mol%; N/P = 4. Methods identify 14:0 PEG2000 PE, whereas the Fig. 1 caption expands the name as a dioleoyl species. Because of this identity inconsistency, the PEG component is not assigned a catalog or molecular weight. It is not replaced by DMG-PEG2000 in this table or calculator.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
SM-102——
DSPC——
Cholesterol——
PEG2000 PE (14:0 in Methods)——

Particle characterization

Experiment / parameterStudy conditionsResult / interpretation
Particle sizeMatched luciferase-mRNA LNPs; Fig. 1cSM-102: 75.5 ± 0.4 nm; ALC-0315: 90.2 ± 7.8 nm; cKK-E12: 88.2 ± 1.5 nm.
RNA encapsulationFig. 1dAll three formulations exceeded 95%.
Apparent pKaFig. 1aThe displayed SM-102 pKa is cited background information, not a new pKa measurement in this study.

Intramuscular reporter expression

Experiment / parameterStudy conditionsResult / interpretation
Model and doseBALB/c mice; 1 µg luciferase mRNA IM; 24 h; n = 6Two independent LNP preparations were used per group (Fig. 1e,f).
Expression comparisonMatched helper-lipid formulationMean bioluminescence for SM-102 was 60% higher than the comparator formulations. ALC-0315 and cKK-E12 were similar under these conditions.

Antibody and inflammatory responses

Experiment / parameterStudy conditionsResult / interpretation
Antibody comparison1 µg antigen mRNA IM, days 1 and 21; n = 10; readouts days 14 and 35SM-102 induced higher neutralizing-antibody responses than ALC-0315 (Fig. 2e,f). Reporter expression alone does not predict antibody output.
Inflammatory panelPlasma 24 h after prime and boostSM-102 and ALC-0315 had comparable cytokine/chemokine responses; cKK-E12 elicited stronger responses for several markers (Fig. 2b; Supplementary Fig. 1).
ScopeShort-term mouse biomarker panelThis is not a comprehensive toxicology assessment or evidence of zero inflammatory activity.

Storage-dependent performance

Experiment / parameterStudy conditionsResult / interpretation
Study designLuciferase-mRNA LNPs in PBS with 10% sucrose; 4°C versus −80°CFollow-up extended to 20 weeks; protein expression, size and encapsulation were measured (Fig. 4).
Refrigerated storage4°CExpression declined after approximately 4–8 weeks; aggregation became evident around 8–12 weeks. SM-102 retained potency better than ALC-0315.
Frozen storage−80°CExpression was maintained across the study period.
Encapsulation versus functionFig. 4b–eEncapsulation remained high despite potency loss at 4°C. Encapsulation alone is therefore insufficient to establish retained delivery activity.

Interpretation and formulation identity

Experiment / parameterStudy conditionsResult / interpretation
Matched comparisonSame helper-lipid mixture across ionizable lipidsThe study supports a comparison of the tested research formulations, not a comparison of marketed vaccine shelf lives.
PEG identityMethods versus Fig. 1 captionThe unresolved PEG naming difference is retained explicitly; DMG-PEG2000 molecular weight 2507 is not used for this phospholipid.

Original study figures

Mouse antibody and inflammatory responses — original Figure 2
Mouse antibody and inflammatory responses — original Figure 2
Zhang L et al., npj Vaccines 8, 156 (2023), Figure 2. Mouse immunization study, cytokine panel and neutralizing-antibody readouts; n = 10 per group. Reproduced unchanged under CC BY 4.0. Interpret significance and error bars with the original caption. Original source and caption · CC BY 4.0

Storage-dependent expression and particle properties — Figure 4 — Original source figures.

References and source locations

  1. Zhang L, et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. npj Vaccines 8, 156 (2023). DOI: 10.1038/s41541-023-00751-6.
  2. Full text, Figures 1–4 and Supplementary Figures 1–4.
CAS No.2089251-47-6
Chemical NameSM-102
SynonymsSM-102;SM 102;SM102
SMILESO=C(OC(CCCCCCCC)CCCCCCCC)CCCCCCCN(CCO)CCCCCC(OCCCCCCCCCCC)=O
FormulaC44H87NO5
M.Wt710.1653
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Zhang L, et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. npj Vaccines 8, 156 (2023). DOI: 10.1038/s41541-023-00751-6.
  2. Full text, Figures 1–4 and Supplementary Figures 1–4.
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Do not substitute DMG-PEG2000 or ALC-0159 for 14:0 PEG2000 PE. N/P 4 is distinct from a lipid:mRNA mass ratio.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg14.0812 mL2.8162 mL1.4081 mL
25 mg35.2031 mL7.0406 mL3.5203 mL
50 mg70.4061 mL14.0812 mL7.0406 mL
100 mg140.8123 mL28.1625 mL14.0812 mL
250 mg352.0307 mL70.4061 mL35.2031 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.